

18<sup>th</sup> Asia Pacific

## OPHTHALMOLOGISTS ANNUAL MEETING

July 29-30, 2019 | Melbourne, Australia

**Comparison of 5-Fluorouracil and Mitomycin-C in primary treatment of ocular surface squamous neoplasia****Akanksha Darda**  
India

**Aim:** To compare efficacy and safety of topical 5-Fluorouracil 1% (5-FU) and Mitomycin C 0.04% (MMC) for Ocular Surface Squamous Neoplasia (OSSN).

**Method:** This retrospective study included 48 patients of primary OSSN. All were treated with 5-FU or MMC. Primary outcome measure was frequency of complete clinical resolution and recurrence rate. Other outcome measures included duration of treatment and adverse effects.

**Results:** 22 eyes were treated with 5-FU and 26 with MMC. Complete response was achieved in 86% and 81% eyes with 5-FU and MMC, respectively ( $P=0.67$ ). Patients were treated with median of three cycles in both groups. Tumor recurrence rate was 7.6% in MMC group while none in 5-FU. The median follow-up after resolution was eight months in 5-FU vs 10 months in MMC. Adverse effects were 18% in 5-FU and 58% in MMC group ( $P<0.005$ ).

**Conclusion:** Both 5-FU and MMC seemed to be equally effective for treatment of OSSN. 5-FU can be preferred as it has lower recurrence rate with minimal side effects over MMC.

akankshadarda@gmail.com